RxDoctor Payments Data

Alexa Robinson

Physician Assistant · Grayson, KYNPI 1548835309

Payments from drug & device makers

$2,485in general payments, 2019–2025

Across 85 payments — averaging $29.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Pfizer$393
  • Myriad Genetic Laboratories, Inc.$224
  • Endo USA, Inc.$215
  • Sumitomo Pharma America, Inc.$214
  • Astellas Pharma US Inc$110
  • plus $259 from 5 others

What the payments were for

  • Travel & lodging$76831%
  • Food & beverage$1,71769%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,485 in reported general payments places this provider in the 80th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$63,970
Medicare patients
507
Services billed
1,450

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron171$133,679
MyrbetriqMirabegron89$60,348
Potassium Citrate ErPotassium Citrate48$8,499
Mirabegron ErMirabegron11$7,894
Tamsulosin Hcl680$7,715
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst206$4,845
Oxybutynin Chloride ErOxybutynin Chloride250$4,603
Finasteride257$2,595
Desmopressin Acetate20$2,117
Bicalutamide40$1,806
Trospium Chloride ErTrospium Chloride12$1,750
Estradiol20$1,607
Alfuzosin Hcl ErAlfuzosin Hcl40$552
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip28$510
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet24$509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$214$133,679171 claims
Astellas Pharma US IncMyrbetriq$110$60,34889 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Grayson

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →